New Drug Applications

The New Drug Application (NDA) is the vehicle through which drug sponsors formally propose that the FDA approve a new pharmaceutical for sale and marketing in the United States.
The purpose of a NDA is to provide enough information to permit the FDA to reach the following key decisions

  • Whether the drug is safe and effective in its proposed use(s), and whether the benefits of the drug outweigh the risks
  • Whether the drug's proposed labeling (package insert) is appropriate and what it should contain
  • Whether the methods used in manufacturing the drug and the controls used to maintain the drug's quality are adequate to preserve the drug's identity, strength, quality, and purity

For more information on New Drug Applications, please visit the FDA's How Drugs are Developed and Approved page.

Get news by email or subscribe to our news feeds.

patiromer for Oral Suspension

Company: Relypsa, Inc.
Treatment for: Hyperkalemia

Patiromer is an oral potassium binder being developed for the treatment of hyperkalemia.

empagliflozin and metformin

Company: Eli Lilly and Company and Boehringer Ingelheim
Treatment for: Diabetes Type 2

Empagliflozin and Metformin is a sodium glucose co-transporter-2 (SGLT2) inhibitor and biguanide combination in development for the treatment of type 2 diabetes.

secukinumab

Company: Novartis Pharmaceuticals Corporation
Treatment for: Plaque Psoriasis

Secukinumab is a selective interleukin-17A (IL-17A) inhibitor in development for the treatment of moderate-to-severe plaque psoriasis.

lenvatinib

Company: Eisai Co., Ltd.
Treatment for: Thyroid Cancer

Lenvatinib is an oral multiple receptor tyrosine kinase (RTK) inhibitor in development for the treatment of progressive radioiodine-refractory differentiated thyroid cancer.

palbociclib

Company: Pfizer Inc.
Treatment for: Breast Cancer

Palbociclib is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor in development for the combination treatment of ER+, HER2- metastatic breast cancer.

drisapersen

Company: Prosensa Holding N.V.
Treatment for: Duchenne Muscular Dystrophy

Drisapersen is an investigational antisense oligonucleotide in development for the treatment of Duchenne Muscular Dystrophy.

blinatumomab

Company: Amgen Inc.
Treatment for: Acute Lymphoblastic Leukemia

Blinatumomab is an investigational bispecific T cell engager (BiTEĀ®) antibody for adults with Philadelphia-negative (Ph-) relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL).

Opdivo (nivolumab)

Company: Bristol-Myers Squibb Company
Treatment for: Melanoma - Metastatic

Opdivo (nivolumab) is an investigational PD-1 immune checkpoint inhibitor in development for the treatment of advanced melanoma.

brincidofovir

Company: Chimerix, Inc.
Treatment for: Ebola Virus Disease

Brincidofovir is a nucleotide analog broad-spectrum antiviral under FDA review to assess the safety and efficacy in patients with confirmed Ebola virus infection.

brexpiprazole

Company: Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S
Treatment for: Schizophrenia, Depression

Brexpiprazole is a serotonin-dopamine activity modulator (SDAM) in development for the treatment of schizophrenia and as adjunctive treatment of major depressive disorder.

Tuzistra XR

Company: Tris Pharma Inc.
Treatment for: Cold Symptoms

Tuzistra XR is extended-release formulation of an undisclosed existing cough and cold product using OralXR+ extended release formulation technology.

Saxenda (liraglutide)

Company: Novo Nordisk Inc.
Treatment for: Obesity

Saxenda (liraglutide) is a once-daily glucagon-like peptide-1 (GLP-1) analogue in development for the treatment of obesity.

Rapivab (peramivir) Injection

Company: BioCryst Pharmaceuticals, Inc.
Treatment for: Influenza

Rapivab (peramivir) is an intravenously administered anti-viral agent in development for the treatment of influenza, including H7N9 and pandemic H1N1 swine flu viral strains.

Keytruda (pembrolizumab) for Injection

Company: Merck & Co., Inc.
Treatment for: Melanoma - Metastatic

Keytruda (pembrolizumab) is a human PD-1 (programmed death receptor-1)-blocking antibody indicated for the treatment of metastatic melanoma.

eluxadoline

Company: Actavis plc
Treatment for: Irritable Bowel Syndrome

Eluxadoline is a combined mu opioid receptor agonist and delta opioid receptor antagonist in development for the treatment of diarrhea predominant irritable bowel syndrome (IBS-D).

evolocumab

Company: Amgen Inc.
Treatment for: Hyperlipidemia

Evolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) in development for the treatment for dyslipidemia.

ivabradine

Company: Amgen Inc.

Ivabradine is an investigational If current ("funny" current) inhibitor for the treatment of chronic heart failure.

See also: Generic Approvals, New Drug Approvals, Recent Additions to Drugs.com, Alphabetical Listing of all New Drug Applications, FDA Approval Process

Older articles
Hide
(web1)